What changed on the page
Added news item: “Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance,” stating that revenue growth was 45% driven by molecular profiling services, including approximately 59,200 clinical cases and over 114,000 whole exome/whole transcriptome tests.